New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
08:09 EDTCOV, NYXCovidien continues relationship with NYSE Euronext
Covidien (COV) announced that Mallinckrodt intends to apply to list its ordinary shares on the New York Stock Exchange, or NYSE, to trade under the symbol MNK. As previously announced, Covidien plans to spin off its Pharmaceuticals business into Mallinckrodt, a stand-alone company, a process expected to be completed in mid-2013. "We are very pleased to continue our relationship with the NYSE and look forward to enhancing our brand image in conjunction with NYSE Euronext (NYX)," said Josť E. Almeida, Chairman, President and CEO. "After a careful review, we decided that Mallinckrodt should be listed on the NYSE. We recognize the value of their deep community, unique visibility opportunities and innovative market structure, and believe it is in the best interest of both companies to be aligned with the NYSE. We look forward to continuing our strong and long engagement with the world's leading global exchange."
News For COV;NYX From The Last 14 Days
Check below for free stories on COV;NYX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 22, 2014
07:01 EDTCOVCovidien acquires Reverse Medical, terms not disclosed
Subscribe for More Information
August 20, 2014
07:18 EDTCOVMedtronic shares have upside with or without deal, says Deutsche Bank
Deutsche Bank sees limited downside risk and significant upside potential for shares of Medtronic (MDT), with or without the pending Covidien (COV) acquisition. Deutsche says the Q1 results show improving trends and it keeps a Buy rating on Medtronic with an $85 price target.
August 19, 2014
08:22 EDTCOVMedtronic: We will continue to pay significant US taxes following Covidien deal
Subscribe for More Information
August 18, 2014
16:10 EDTCOVCovidien says study shows directional atherectomy safe, effective
Covidien announced that directional atherectomy is "safe and effective as a frontline therapy for the treatment of peripheral arterial disease," according to a Covidien study published online today in the Journal of American College of Cardiology, Cardiovascular Interventions. Results from the DEFINITIVE LE study using Covidienís TurboHawk and/or SilverHawk directional atherectomy systems demonstrated 95% limb salvage in patients with critical limb ischemia and 78% overall patency in claudicant patients at 12 months.
August 14, 2014
17:16 EDTCOVPaulson & Co gives quarterly update on stakes
Subscribe for More Information
07:27 EDTCOVJPMorgan a buyer of Medtronic at current levels
Subscribe for More Information
06:15 EDTCOVCovidien risk/reward very favorable, says Citigroup
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use